Physician profile
Mark L Chalem
NPI 1083830848
$1,075.72
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $918 · 2020: $110 · 2022: $46.91.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $249.74 | 2019-2020 | |
| Allergan, INC. | $204.36 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $143.46 | 2019 | |
| Janssen Pharmaceuticals, INC | $98.20 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $66.73 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $60.08 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $56.91 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.91 | 2022 | |
| Neurocrine Biosciences, INC. | $43.99 | 2019 | |
| Lundbeck LLC | $33.64 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $20.62 | 2019 | |
| Shire North American Group INC | $18.83 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.56 | 2019 | |
| Alfasigma USA, INC. | $15.69 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Chalem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.